全文获取类型
收费全文 | 3165178篇 |
免费 | 235343篇 |
国内免费 | 8766篇 |
专业分类
耳鼻咽喉 | 43953篇 |
儿科学 | 102251篇 |
妇产科学 | 88723篇 |
基础医学 | 446794篇 |
口腔科学 | 88758篇 |
临床医学 | 286998篇 |
内科学 | 619543篇 |
皮肤病学 | 73819篇 |
神经病学 | 259350篇 |
特种医学 | 122649篇 |
外国民族医学 | 891篇 |
外科学 | 477466篇 |
综合类 | 69364篇 |
现状与发展 | 7篇 |
一般理论 | 1182篇 |
预防医学 | 245172篇 |
眼科学 | 72114篇 |
药学 | 232617篇 |
8篇 | |
中国医学 | 6410篇 |
肿瘤学 | 171218篇 |
出版年
2018年 | 33896篇 |
2017年 | 26156篇 |
2016年 | 30164篇 |
2015年 | 34212篇 |
2014年 | 47479篇 |
2013年 | 71748篇 |
2012年 | 94929篇 |
2011年 | 100307篇 |
2010年 | 60263篇 |
2009年 | 57642篇 |
2008年 | 93872篇 |
2007年 | 100159篇 |
2006年 | 101691篇 |
2005年 | 97814篇 |
2004年 | 94499篇 |
2003年 | 91452篇 |
2002年 | 88154篇 |
2001年 | 147753篇 |
2000年 | 151114篇 |
1999年 | 127745篇 |
1998年 | 37321篇 |
1997年 | 33338篇 |
1996年 | 33331篇 |
1995年 | 32162篇 |
1994年 | 29700篇 |
1993年 | 27891篇 |
1992年 | 100996篇 |
1991年 | 97453篇 |
1990年 | 94630篇 |
1989年 | 91474篇 |
1988年 | 84068篇 |
1987年 | 82613篇 |
1986年 | 77678篇 |
1985年 | 74382篇 |
1984年 | 55854篇 |
1983年 | 47577篇 |
1982年 | 28712篇 |
1981年 | 25848篇 |
1979年 | 50964篇 |
1978年 | 36350篇 |
1977年 | 30768篇 |
1976年 | 28511篇 |
1975年 | 30580篇 |
1974年 | 36508篇 |
1973年 | 34772篇 |
1972年 | 32797篇 |
1971年 | 30401篇 |
1970年 | 28290篇 |
1969年 | 27280篇 |
1968年 | 25009篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
M. C. van den Heuvel K. P. de Jong M. Boot M. J. H. Slooff S. Poppema A. S. H. Gouw 《American journal of transplantation》2006,6(11):2660-2671
The finer branches of the biliary tree (FBBT) contain a regenerative compartment. We hypothesized that preservation of the FBBT together with its microvasculature will lead to recovery of biliary damage and prolonged preservation of bile ductules during the development of chronic liver allograft rejection. The interlobular bile ducts, portal bile ductules and extraportal biliary cells with and without microvessels were studied in sequential biopsies in five patients who fulfilled the Banff criteria of early chronic rejection (CR) (imminence group). Biopsies of CR patients (n = 12) served as controls. Biopsies were double immunostained with CD34 (microvessels) and cytokeratin 7 (biliary structures). Proliferation and proangiogenic activity were assessed with Ki67 and VEGF-A immunostaining. Severe damage of bile ducts in the imminence group did not progress to significant bile duct loss. This was associated with a high proliferative activity in all biliary structures and preservation of the microvascular compartment. VEGF-A expression was increased in all but the reperfusion biopsies. In conclusion, both regenerative activity of the FBBT and an intact microvascular compartment are associated with less damage of the biliary tree and could therefore be prerequisites for biliary regeneration. 相似文献
992.
S. Vitko Z. Wlodarczyk L. Kyllönen Z. Czajkowski R. Margreiter L. Backman F. Perner P. Rigotti B. Jaques D. Abramowicz M. Kessler J. Sanchez-Plumed L. Rostaing R.S. Rodger D. Donati Y. Vanrenterghem 《American journal of transplantation》2006,6(3):531-538
Tacrolimus combined with mycophenolate mofetil (MMF) is an effective regimen in kidney transplantation. This study compared the efficacy of combining tacrolimus and two different dosages of sirolimus with an established tacrolimus-MMF regimen. Each day in addition to tacrolimus, 325 patients received 2 mg sirolimus (TAC-SRL2 mg), 325 patients received 0.5 mg sirolimus (TAC-SRL0.5 mg) and 327 patients 1 g MMF (TAC-MMF). The initial tacrolimus dose was 0.2 mg/kg/day. Sirolimus patients received loading doses of 6 or 1.5 mg, and daily doses of 2 or 0.5 mg thereafter. Steroid administration was identical for all groups. The incidence of biopsy-proven acute rejection was lower in the TAC-SRL2 mg group (15.7%) compared with the TAC-SRL0.5 mg (25.2%, p = 0.003) and the TAC-MMF groups (22.3%, p = 0.036). Six-month graft survival was 91.0% (TAC-SRL2 mg), 92.6% (TAC-SRL0.5 mg) and 92.4% (TAC-MMF); the respective values for patient survival were 98.1%, 97.8% and 97.9%. Thirty-four patients (10.5%), 19 patients (5.8%) and 16 patients (4.9%) in the TAC-SRL2 mg, TAC-SRL0.5 mg and TAC-MMF groups, respectively, discontinued the study because of adverse events. Hyperlipemia was reported more often in the TAC-SRL2 mg group (24.0%) compared with 19.4% (TAC-SRL0.5 mg) and 11.0% (TAC-MMF; p < 0.05). Combining 2 mg sirolimus/day with tacrolimus results in lower rates of acute rejection, but a higher incidence of adverse events. 相似文献
993.
994.
995.
M. Naumann A. Albanese F. Heinen G. Molenaers M. Relja 《European journal of neurology》2006,13(S4):35-40
Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX® . These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications. 相似文献
996.
997.
998.
999.
1000.